Effects of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular Outcomes and All-Cause Mortality: A Comprehensive Network Meta-analysis

被引：0
作者：
Tang, Huilin
Fang, Zhenwei
Wang, Tiansheng
Song, Yiqing
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1386-P
引用
收藏
页码：A363 / A363
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis
    El Masri, Dana
    Ghosh, Samiran
    Jaber, Linda A.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 137 : 83 - 92
  • [22] Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis
    Heyward, James
    Mansour, Omar
    Olson, Lily
    Singh, Sonal
    Alexander, G. Caleb
    [J]. PLOS ONE, 2020, 15 (06):
  • [23] Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
    Steinberg, Helmut O.
    [J]. POSTGRADUATE MEDICINE, 2016, 128 (04) : 398 - 408
  • [24] Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials
    Eraikhuemen, Nathaniel
    Leung, Simon
    Warren, Shalonda Barnes
    Lazaridis, Dovena
    Smith, Carla Hawkins
    Kearson, Margaretta L.
    Marcellus, Valerie
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (02) : 113 - 126
  • [25] Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials
    Nathaniel Eraikhuemen
    Simon Leung
    Shalonda Barnes Warren
    Dovena Lazaridis
    Carla Hawkins Smith
    Margaretta L. Kearson
    Valerie Marcellus
    [J]. American Journal of Cardiovascular Drugs, 2023, 23 : 113 - 126
  • [26] Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world
    MacIsaac, Richard J.
    Ekinci, Elif I.
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)
  • [27] Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update
    Salah, Husam M.
    Al'Aref, Subhi J.
    Khan, Muhammad Shahzeb
    Al-Hawwas, Malek
    Vallurupalli, Srikanth
    Mehta, Jawahar L.
    Mounsey, J. Paul
    Greene, Stephen J.
    McGuire, Darren K.
    Lopes, Renato D.
    Fudim, Marat
    [J]. AMERICAN HEART JOURNAL, 2021, 233 : 86 - 91
  • [28] Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials
    Silverii, Giovanni Antonio
    Monami, Matteo
    Mannucci, Edoardo
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (04) : 1052 - 1056
  • [29] Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide
    Simes, Bryce C.
    MacGregor, Gordon G.
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2125 - 2136
  • [30] Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
    Berbari, Adel E.
    [J]. INTERNATIONAL JOURNAL CARDIOLOGY HYPERTENSION, 2020, 7
12345